Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan

Journal of Gynecologic Oncology

Volumn 24, Issue 4, 2013, Pages 342-351

  Chiang, Ying Cheng ^a   Chen, Chi An ^a   Chiang, Chun Ju ^b   Hsu, Tsui Hsia ^c   Lin, Ming Chieh ^a   You, San Lin ^d,e   Cheng, Wen Fang ^a   Lai, Mei Shu ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c DEPARTMENT OF HEALTH   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Epithelial ovarian carcinoma; Histological type; Population based study; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CARCINOSARCOMA; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; GASTROINTESTINAL TRACT; HISTOLOGY; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; STOMACH CANCER; SURVIVAL RATE; TAIWAN; UNDIFFERENTIATED CARCINOMA;

EID: 84885638976     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2013.24.4.342     Document Type: Article

References (49)

1. Huang YW, Kuo CT, Stoner K, Huang TH, Wang LS. An overview of epigenetics and chemoprevention. FEBS Lett 2011;585:2129-36.
2. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16.
3. Kurman RJ, Shih IEM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
4. International Agency for Research on Cancer. CI5plus: cancer incidence in five continents annual dataset [Internet]. Cedex: International Agency for Research on Cancer; [cited 2013 Aug 20]. Available from: http://ci5.iarc.fr/CI5plus/ci5plus.htm.
5. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108(3 Pt 1):521-8.
6. Cabanes A, Vidal E, Perez-Gomez B, Aragones N, Lopez-Abente G, Pollan M. Age-specific breast, uterine and ovarian cancer mortality trends in Spain: changes from 1980 to 2006. Cancer Epidemiol 2009;33:169-75.
7. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2005;113:977-90.
8. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120-7.
9. Gonzalez-Diego P, Lopez-Abente G, Pollan M, Ruiz M. Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. Eur J Cancer 2000;36:1816-24.
10. Health Promotion Administration, Ministry of Health and Welfare. National Cancer Registry [Internet]. [cited 2013 Aug 20]. Available from: http://www.bhp.doh.gov.tw/BHPNET/Portal/StatisticsShow.aspx?No=200911300001.
11. Chiang CJ, Chen YC, Chen CJ, You SL, Lai MS; Taiwan Cancer Registry Task Force. Cancer trends in Taiwan. Jpn J Clin Oncol 2010;40:897-904.
12. Tavassoeli FA. World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC press; 2003.
13. Leen SL, Singh N. Pathology of primary and metastatic mucinous ovarian neoplasms. J Clin Pathol 2012;65:591-5.
14. McCluggage WG. Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms. J Clin Pathol 2012;65:596-600.
15. Young RH. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol 2007;14:149-77.
16. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003;27:985-93.
17. Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 2005;24:4-25.
18. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol 2013;129:258-64.
19. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012;55:3-23.
20. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-14.
21. Chow LP, Nair NK. Oral contraceptive use and diseases of the circulatory system in Taiwan: an analysis of mortality statistics. Int J Gynaecol Obstet 1980;18:420-32.
22. Wang TM, Liu Y. Re-examination of Taiwan-s total fertility rate: an application of the ACF method. J Popul Stud 2008;36:37-65.
23. Lin YC, Yen LL, Chen SY, Kao MD, Tzeng MS, Huang PC, et al. Prevalence of overweight and obesity and its associated factors: findings from National Nutrition and Health Survey in Taiwan, 1993-1996. Prev Med 2003;37:233-41.
24. Lin CH, Chen YC, Chiang CJ, Lu YS, Kuo KT, Huang CS, et al. The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer 2012;130:2629-37.
25. Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC, et al. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer 2008;44:2477-84.
26. Vlahos NF, Kalampokas T, Fotiou S. Endometriosis and ovarian cancer: a review. Gynecol Endocrinol 2010;26:213-9.
27. Fang GC, Wu YS, Fu PP, Yang IL, Chen MH. Polycyclic aromatic hydrocarbons in the ambient air of suburban and industrial regions of central Taiwan. Chemosphere 2004;54:443-52.
28. Chen CY, Wen TY, Wang GS, Cheng HW, Lin YH, Lien GW. Determining estrogenic steroids in Taipei waters and removal in drinking water treatment using high-flow solid-phase extraction and liquid chromatography/tandem mass spectrometry. Sci Total Environ 2007;378:352-65.
29. Chen ML, Chen JS, Tang CL, Mao IF. The internal exposure of Taiwanese to phthalate--an evidence of intensive use of plastic materials. Environ Int 2008;34:79-85.
30. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-7.
31. Ioka A, Tsukuma H, Ajiki W, Oshima A. Ovarian cancer incidence and survival by histologic type in Osaka, Japan. Cancer Sci 2003; 94:292-6.
32. Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer 2006;95:1314-20.
33. Gatta G, Capocaccia R, DeAngelis R, Stiller C, Coebergh JW; EUROCARE Working Group. Cancer survival in European adolescents and young adults. Eur J Cancer 2003;39:2600-10.
34. Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol 2003;102:156-61.
35. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994;10:31-46.
36. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
37. Hirabayashi Y, Marugame T. Comparison of time trends in ovary cancer mortality (1990-2006) in the world, from the WHO Mortality Database. Jpn J Clin Oncol 2009;39:860-1.
38. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:2873-83.
39. Wakabayashi MT, Lin PS, Hakim AA. The role of cytoreductive/ debulking surgery in ovarian cancer. J Natl Compr Canc Netw 2008;6:803-10.
40. Tan W, Stehman FB, Carter RL. Mortality rates due to gynecologic cancers in New York state by demographic factors and proximity to a Gynecologic Oncology Group member treatment center: 1979-2001. Gynecol Oncol 2009;114:346-52.
41. Chan JK, Sherman AE, Kapp DS, Zhang R, Osann KE, Maxwell L, et al. Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol 2011;29:832-8.
42. Stewart SL, Rim SH, Richards TB. Gynecologic oncologists and ovarian cancer treatment: avenues for improved survival. J Womens Health (Larchmt) 2011;20:1257-60.
43. Taiwan Association of Gynecologic Oncologists. TAGO [Internet]. Taiwan: TAGO; [cited 2013 Aug 20]. Available from: http://www.tago.org.tw/eng/about.asp.
44. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
45. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000;18:106-15.
46. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9.
47. Kumar S, Mahdi H, Bryant C, Shah JP, Garg G, Munkarah A. Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health 2010;2:411-27.
48. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
49. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.